Effects of Metronomic Chemotherapy of Low-Dose Paclitaxel on the Proliferation and Microvasculature of Lewis Lung Cancer Cells

徐绘,黄桂春,陈龙邦
DOI: https://doi.org/10.3969/j.issn.1008-8199.2010.03.007
2010-01-01
Abstract:Objective As a new anticancer method,metronomic chemotherapy with low-dose chemotherapeutic drugs might be different from traditional chemotherapy in administration,side-reaction and mechanisms.Our experiment was to explore the effects of the metronomic chemotherapy of paclitaxel on tumor growth and microenvironment of Lewis cells subcutaneous transplanted tumor.Methods Lewis lung cancer cells were subcutaneously injected into C57/BL6 mice to establish in vivo models,which were given paclitaxel at 2 mg/kg ip daily(low dose),paclitaxel at 20 mg/kg ip once(conventional dose) and normal saline ip daily(control group),respectively.The tumor volumes were recorded daily,and tumor samples obtained at 14 and 28 d after the treatment.Evans Blue was used as a marker for the determination of vascular permeability and rate of tumor necrosis.The expressions of vascular endothelial growth factor-A(VEGF-A),thrombospodin-1(TSP-1) and the regulator of G-protein signaling 5(Rgs 5) were examined by semi-quantitative RT-PCR.Results Compared with the conventional-dose and control groups,low-dose paclitaxel metronomic chemotherapy significantly inhibited the growth of Lewis lung cancer(P 0.01),with higher blood perfusion and a lower rate of tumor necrosis,up-regulated the expression of VEGF-A(P 0.05),and down-regulated the expressions of TSP-1 and Rgs 5(P 0.05).Conclusion Low-dose metronomic paclitaxel could inhibit the growth in vivo of Lewis lung cancer,and influence tumor microvasculature by regulating the expressions of VEGF-A,TSP-1 and Rgs 5.
What problem does this paper attempt to address?